Soligenix (NASDAQ:SNGX) Shares Cross Above 200 Day Moving Average of $0.93

Soligenix, Inc. (NASDAQ:SNGX) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.93 and traded as high as $1.03. Soligenix shares last traded at $0.99, with a volume of 1,000 shares trading hands.

SNGX has been the subject of a number of recent analyst reports. ValuEngine raised Soligenix from a “sell” rating to a “hold” rating in a research report on Wednesday, November 27th. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of Soligenix in a report on Wednesday.

The firm has a market capitalization of $21.27 million, a price-to-earnings ratio of -1.49 and a beta of 1.32. The company has a fifty day moving average of $0.95 and a two-hundred day moving average of $0.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.42 and a current ratio of 1.42.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.40 million. Soligenix had a negative return on equity of 212.69% and a negative net margin of 193.39%. Equities analysts forecast that Soligenix, Inc. will post -0.46 EPS for the current year.

An institutional investor recently raised its position in Soligenix stock. Vanguard Group Inc. increased its position in shares of Soligenix, Inc. (NASDAQ:SNGX) by 23.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 412,158 shares of the biopharmaceutical company’s stock after purchasing an additional 76,955 shares during the period. Vanguard Group Inc. owned approximately 2.10% of Soligenix worth $293,000 as of its most recent filing with the Securities and Exchange Commission. 9.89% of the stock is owned by hedge funds and other institutional investors.

Soligenix Company Profile (NASDAQ:SNGX)

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit